FDA approves Polatuzumab Vedotin Plus R-CHP for previously untreated DLBCL
fitness

FDA approves Polatuzumab Vedotin Plus R-CHP for previously untreated DLBCL

/

This article originally appeared on OncLive. This version has been slightly modified. The FDA has approved polatuzumab vedotin-piiq (Polivy) plus […]